טוען...
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide(1). Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC patients(2,3); therefore, alternative drug targets, including epigenetic enzymes,...
שמור ב:
| הוצא לאור ב: | Nature |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4393352/ https://ncbi.nlm.nih.gov/pubmed/25629630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14122 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|